NCIt definition : The hydrochloride salt form of an orally bioavailable multitargeted receptor tyrosine
kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities.
Ponatinib inhibits unmutated and all mutated forms of Bcr-Abl, including T315I, the
highly drug therapy-resistant missense mutation of Bcr-Abl. This agent also inhibits
other tyrosine kinases including those associated with vascular endothelial growth
factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs); in addition,
it inhibits the tyrosine kinase receptor TIE2 and FMS-related tyrosine kinase receptor-3
(Flt3). RTK inhibition by ponatinib may result in the inhibition of cellular proliferation
and angiogenesis and may induce cell death. Bcr-Abl is a fusion tyrosine kinase encoded
by the Philadelphia chromosome.;